On this episode, we’ll hear about a study that examined the impact of the time of day that a patient with advanced melanoma receives an immune checkpoint inhibitor infusion on overall survival. Then, we’ll hear about two recent approvals from the FDA—one in relapsed or refractory multiple myeloma, and one for identification of ovarian cancer lesions during surgery.

Coverage of stories discussed this week on ascopost.com:

Impact of Time of Day of Immune Checkpoint Inhibitor Infusion on Overall Survival in Patients With Metastatic Melanoma

FDA Approves Triplet Therapy for Previously Treated Patients With Relapsed or Refractory Multiple Myeloma

FDA Approves Pafolacianine to Help Identify Ovarian Cancer Lesions

To listen to more podcasts from ASCO, visit asco.org/podcasts.